Call us: 1.405.235.2305
info@i2E.org
  • Events
  • News
  • Resources
  • Media
  • Love’s Cup
i2Ei2Ei2Ei2E
  • About
  • Entrepreneurship
    • Venture Advisory Services
    • Love’s Entrepreneur’s Cup
  • e3
  • Concept Fund
  • iMCI
  • Portfolio
  • ACT Tulsa
  • Contact

News

AscendBioVentures BIO

By sarah | OKBio | 0 comment | 13 June, 2022 | 0

To read the full 2022 i&E OKBIO Edition, click here.Read more

Autigen Announces Collaboration with Boehringer Ingelheim

By sarah | News | 0 comment | 18 April, 2022 | 0

Novel Treatments for Hearing Loss Collaboration and licensing agreement to advance novel therapies for sensorineural hearing loss (SNHL), where there are currently no approved pharmacological therapies. OKLAHOMA CITY–(BUSINESS WIRE)– Autigen, a biotechnology portfolio company of the pharmaceutical accelerator, Ascend BioVentures, developing novel treatments for hearing loss, announced today that it has signed a research collaboration and license agreementRead more

i2E-300dpi-Trans-Light
  • Events
  • News
  • Resources
  • Media
  • Love’s Cup

Oklahoma City Office

840 Research Parkway, Suite 250
OKC, OK 73104
PHONE 405/235-2305
Click HERE for printable map with directions.

Tulsa Office

100 S. Cincinnati Ave – 5th Floor, Suite 514
Tulsa, OK 74103
PHONE 918/582-5592
Copyright 2022 i2E, Inc. | All Rights Reserved
  • About
  • Entrepreneurship
    • Venture Advisory Services
    • Love’s Entrepreneur’s Cup
    • ACT Tulsa
  • e3
  • Concept Fund
  • Portfolio
  • iMCI
  • ACT Tulsa
  • Contact
i2E